肿瘤细胞治疗研究
英文原题：Clinical outcomes and spatial transcriptomic profiles of CD19/20 CAR-T therapy in relapsed or refractory B-cell non-Hodgkin's lymphoma.
双特异性 CD19/20 CAR-T 疗法产生了持久的临床活性，且毒性可控。
背景：尽管已有 CD19 靶向嵌合抗原受体（CAR）T 细胞疗法，复发或难治性（R/R）B 细胞非霍奇金淋巴瘤（B-NHL）仍是重大治疗挑战，治疗失败常由抗原逃逸和 CAR-T 持续性不足导致。联合靶向 CD19 和 CD20 可能减轻抗原丢失问题。研究者开展一项扩展的 I/II 期双特异性 CD19/20 CAR-T 研究，并结合空间分辨单细胞转录组分析，评估影响临床应答的肿瘤内在和微环境因素。 方法：R/R B-NHL 患者在淋巴细胞清除后接受 CD19/20 CAR-T。评估疗效、安全性、CAR-T 扩增/持续性和 B 细胞重建。对治疗结局不同的 5 名患者治疗前肿瘤活检进行空间单细胞转录组分析。 结果：共治疗 32 名患者，其中 24 名为弥漫性大 B 细胞淋巴瘤。31 名可评估患者的最佳总缓解率为 74%，其中 58% 达到完全缓解。无进展生存期和总生存期中位数分别为 6.8 和 22.1 个月。乳酸脱氢酶正常患者应答率较高。CAR-T 扩增高峰出现在第 7–17 天，长期应答者的持续时间超过 500 天。细胞因子释放综合征发生率为 53%（3 级 12%）；免疫效应细胞相关神经毒性综合征发生率为 9%（均为 3 级），且无持续性神经功能缺损。空间分析确定两种主要肿瘤结构：（1）B 细胞占主导型，其中持久缓解与恶性 B 细胞凋亡能力增强相关；（2）成纤维细胞及单核/巨噬细胞富集型，其中应答与富含趋化因子、利于 T 细胞进入的微环境相关。 结论：双特异性 CD19/20 CAR-T 产生了持久临床活性，毒性可管理。空间单细胞分析揭示与 CAR-T 应答相关的不同肿瘤内在和微环境特征，为理解治疗结局异质性提供空间层面的框架。试验注册号：NCT04723914。
BACKGROUND: Relapsed or refractory (R/R) B-cell non-Hodgkin's lymphoma (B-NHL) remains a major therapeutic challenge despite CD19-directed chimeric antigen receptor (CAR) T-cell therapies, with treatment failure often driven by antigen escape and limited CAR-T persistence. Dual targeting of CD19 and CD20 may mitigate antigen loss. We conducted an expanded phase I/II study of bispecific CD19/20 CAR-T cells and incorporated spatially resolved single-cell transcriptomics to evaluate tumor-intrinsic and microenvironmental factors of clinical response. METHODS: Patients with R/R B-NHL received CD19/20 CAR-T cells following lymphodepletion. Efficacy, safety, CAR-T expansion/persistence, and B-cell reconstitution were assessed. Pretreatment tumor biopsies from five patients with divergent outcomes underwent spatial single-cell transcriptomic profiling. RESULTS: 32 patients were treated, including 24 with diffuse large B-cell lymphoma. Among 31 evaluable patients, the best overall response rate was 74%, including 58% achieving complete remission. Median progression-free and overall survival were 6.8 and 22.1 months, respectively. Response rates were higher in patients with normal lactate dehydrogenase. CAR-T expansion peaked on days 7-17, and persistence exceeded 500 days in long-term responders. Cytokine release syndrome occurred in 53% (12% grade 3) and immune effector cell-associated neurotoxicity syndrome in 9% (all grade 3), with no lasting deficits. Spatial profiling identified two dominant tumor architectures: (1) a B-cell-dominant phenotype, in which durable remission was associated with heightened apoptotic competence in malignant B cells, and (2) a fibroblast-enriched and monocyte/macrophage-enriched phenotype, in which response correlated with a chemokine-rich, T-cell-permissive microenvironment. CONCLUSIONS: Bispecific CD19/20 CAR-T therapy produced durable clinical activity with manageable toxicity. Spatial single-cell analysis reveals distinct tumor-intrinsic and microenvironmental features associated with CAR-T responsiveness, providing a spatially informed framework for understanding heterogeneous therapeutic outcomes. TRIAL REGISTRATION NUMBER: NCT04723914.
MEMBER ACCOUNT
登录成功会直接打开下一页。
